Laboratory of Neurooncology, Croatian Institute for Brain Research, School of Medicine University of Zagreb, Zagreb, Croatia.
J Neurooncol. 2010 Mar;97(1):143-8. doi: 10.1007/s11060-009-0001-7. Epub 2009 Aug 27.
The study analyzes exon 15 of the adenomatous polyposis coli gene (APC) in a 49-year-old male patient with brain metastasis. The primary site was lung carcinoma. PCR method and direct DNA sequencing of the metastasis and autologous lymphocyte samples identified the presence of a somatic mutation. The substitution was at position 5883 G-A in the metastasis tissue. The mutation was confirmed by RFLP analysis using Msp I endonuclease, since the mutation strikes the Msp I restriction site. Immunohistochemical analysis revealed the lack of protein expression of this tumor suppressor gene. The main molecular activator of the wnt pathway, beta-catenin, was expressed, and located in the nucleus. The mutation is a silent mutation that might have consequences in the creation of a new splice site. Different single-base substitutions in APC exons need not only be evaluated by the predicted change in amino acid sequence, but rather at the nucleotide level itself. In our opinion, such silent mutations should also be incorporated in mutation detection rate and validation.
本研究分析了一名 49 岁男性脑转移患者腺瘤性结肠息肉基因(APC)外显子 15 的情况。该患者的原发性疾病为肺癌。通过转移和自体淋巴细胞样本的 PCR 方法和直接 DNA 测序,发现存在一种体细胞突变。该突变位于转移组织中的 5883 位 G-A。该突变通过 Msp I 内切酶的 RFLP 分析得到确认,因为该突变影响了 Msp I 限制位点。免疫组化分析显示该肿瘤抑制基因的蛋白表达缺失。wnt 通路的主要分子激活剂β-连环蛋白表达,并位于细胞核中。该突变是一种沉默突变,可能会在创建新的剪接位点方面产生影响。不同的 APC 外显子中的单个碱基替换不仅需要根据预测的氨基酸序列变化进行评估,还需要在核苷酸水平本身进行评估。在我们看来,这种沉默突变也应该纳入突变检测率和验证中。